IP Library Granted Patent US 12702685
Granted Patent B2
US 12702685 · App. 18/413,678 · Granted Aug 11, 2026

Attenuated

Inventors: Kwangsoo Kim (Gwangju, KR); Jong-eun Lee (Seoul, KR); Sol Choy (Seoul, KR)
Assignee: ODYSSEUS BIO CO., LTD.
A61K35/74A61P35/00C07K14/195C07K14/55C12N15/74C07K2319/00C12R2001/42
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12702685
App. No.
18/413,678
Granted
Aug 11, 2026
Kind
B2
Abstract

Disclosed are attenuated Salmonella gallinarum expressing FliC (flagellin) or FliC-hIL2 (human IL2 fused to FliC) and use thereof, wherein the Salmonella strain exhibits excellent immune activation ability and anticancer efficacy and thus can be used as a cancer therapeutic agent, together with or independently from existing anticancer agents.

Claims (3)

1 . A method for treating, preventing, alleviating, or inhibiting cancer, comprising administering to a subject in need thereof a pharmaceutical composition comprising as an active ingredient,

a Salmonella gallinarum strain into which a vector containing a polynucleotide encoding IL-2 (interleukin-2) fused with FliC (a filament structural protein) is introduced,

wherein the polynucleotide encoding IL-2 fused with FliC includes the sequence of SEQ ID NO: 3.